Priyanka Grover
Stock Analyst at J.P. Morgan
(0.16)
# 4,614
Out of 4,988 analysts
24
Total ratings
18.8%
Success rate
-29.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Priyanka Grover
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | n/a | $96.77 | - | 3 | Sep 16, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterated: Buy | n/a | $4.88 | - | 4 | Sep 15, 2026 | |
| MREO Mereo BioPharma Group | Reiterated: Sell | n/a | $0.285 | - | 9 | Sep 15, 2026 | |
| NUVB Nuvation Bio | Reiterated: Buy | n/a | $5.80 | - | 2 | Sep 15, 2026 | |
| RXRX Recursion Pharmaceuticals | Reiterated: Buy | n/a | $3.24 | - | 3 | Sep 15, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | $31 | $18.97 | +63.42% | 3 | Aug 14, 2026 |
Rhythm Pharmaceuticals
Sep 16, 2026
Reiterated: Buy
Price Target: n/a
Current: $96.77
Upside: -
BridgeBio Oncology Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.88
Upside: -
Mereo BioPharma Group
Sep 15, 2026
Reiterated: Sell
Price Target: n/a
Current: $0.285
Upside: -
Nuvation Bio
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.80
Upside: -
Recursion Pharmaceuticals
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.24
Upside: -
Relay Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $31
Current: $18.97
Upside: +63.42%